Esperion Therapeutics Net Worth
Esperion Therapeutics Net Worth Breakdown | ESPR |
Esperion Therapeutics Net Worth Analysis
Esperion Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Esperion Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Esperion Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Esperion Therapeutics' net worth analysis. One common approach is to calculate Esperion Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Esperion Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Esperion Therapeutics' net worth. This approach calculates the present value of Esperion Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Esperion Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Esperion Therapeutics' net worth. This involves comparing Esperion Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Esperion Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Esperion Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Esperion Therapeutics' net worth research are outlined below:
| Esperion Therapeutics generated a negative expected return over the last 90 days | |
| Esperion Therapeutics has high historical volatility and very poor performance | |
| Esperion Therapeutics may become a speculative penny stock | |
| Esperion Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 116.33 M. Net Loss for the year was (209.25 M) with profit before overhead, payroll, taxes, and interest of 188.03 M. | |
| Esperion Therapeutics currently holds about 185.84 M in cash with (135.49 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.79, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Esperion Therapeutics has a very weak financial position based on the latest SEC disclosures | |
| Roughly 66.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635 |
Esperion Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Esperion Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Esperion Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Esperion Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Esperion Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Esperion Therapeutics backward and forwards among themselves. Esperion Therapeutics' institutional investor refers to the entity that pools money to purchase Esperion Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Millennium Management Llc | 2024-09-30 | 3.4 M | Centerbook Partners Lp | 2024-09-30 | 3.1 M | Marshall Wace Asset Management Ltd | 2024-09-30 | 3.1 M | Indaba Capital Management, Llc | 2024-12-31 | 3 M | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 2.6 M | Woodline Partners Lp | 2024-09-30 | 2.2 M | Nuveen Asset Management, Llc | 2024-09-30 | 2.1 M | Rhenman Partners Asset Management Ab | 2024-12-31 | 1.9 M | Deutsche Bank Ag | 2024-09-30 | 1.6 M | Wasatch Advisors Lp | 2024-09-30 | 23.3 M | Blackrock Inc | 2024-09-30 | 14.3 M |
Follow Esperion Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 366.49 M.Market Cap |
|
Project Esperion Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.92) | (0.96) | |
| Return On Capital Employed | (2.82) | (2.68) | |
| Return On Assets | (0.92) | (0.96) | |
| Return On Equity | 0.41 | 0.43 |
When accessing Esperion Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Esperion Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Esperion Therapeutics' profitability and make more informed investment decisions.
Evaluate Esperion Therapeutics' management efficiency
Esperion Therapeutics has return on total asset (ROA) of 0.0384 % which means that it generated a profit of $0.0384 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.6079) %, meaning that it created substantial loss on money invested by shareholders. Esperion Therapeutics' management efficiency ratios could be used to measure how well Esperion Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 02/17/2025, Return On Equity is likely to grow to 0.43, while Return On Tangible Assets are likely to drop (0.96). As of 02/17/2025, Debt To Assets is likely to grow to 2.48, while Total Assets are likely to drop slightly above 181.9 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (5.07) | (4.82) | |
| Tangible Book Value Per Share | (5.08) | (4.82) | |
| Enterprise Value Over EBITDA | (5.88) | (6.17) | |
| Price Book Value Ratio | (0.61) | (0.64) | |
| Enterprise Value Multiple | (5.88) | (6.17) | |
| Price Fair Value | (0.61) | (0.64) | |
| Enterprise Value | 690.3 M | 549.2 M |
Effective leadership at Esperion Therapeutics drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Enterprise Value Revenue 1.661 | Revenue | Quarterly Revenue Growth 0.52 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Esperion Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Esperion Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Esperion Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Esperion Therapeutics time-series forecasting models is one of many Esperion Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Esperion Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Esperion Therapeutics Earnings per Share Projection vs Actual
Esperion Therapeutics Corporate Management
| Benjamin JD | General Secretary | Profile | |
| Benjamin MBA | Chief Officer | Profile | |
| Glenn Brame | Chief Officer | Profile | |
| Tiffany MBA | Associate Communications | Profile | |
| Ben MBA | Chief Officer | Profile | |
| Betty Swartz | Chief Officer | Profile |
Additional Tools for Esperion Stock Analysis
When running Esperion Therapeutics' price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.